NASDAQ$TNGX

Tango Therapeutics Inc · Q3 2025 earnings

Q3 2025 earnings · · Before market open · Investor relations

Briefing

Tango Therapeutics reported Q3 2025, revenue of $53.8M, net income of $15.9M, diluted EPS of $0.13.

For Q3 2025, Tango Therapeutics reported revenue of $53.8M, net income of $15.9M, diluted EPS of $0.13. Management discusses operating trends, liquidity, and priorities as disclosed in the filing.

  • Revenue $53.8M.
  • Net income $15.9M.
  • Diluted EPS $0.13.

Headline financials

Total Revenue

$53.8M

Previous: $11.6M+363.6%
EPS (adj)

$0.13

Previous: -$0.27+148.1%
Capital Expenditures

-$826K

Previous: -$630K-31.1%
Free Cash Flow

$15.1M

Previous: -$29.8M+150.5%
Net Income

$15.9M

Previous: -$29.2M+154.5%
Operating Income

$14.1M

Previous: -$32.9M+142.8%
Gross Profit

$53.8M

Previous: $11.6M+363.6%

Revenue & EPS history

Tango Therapeutics · Revenue · Quarterly

$53.8M

Q3 2025+363.6%vs Q3 2024
Beat estimate in 6 of 13 quarters(46%)
ActualEstimate

Forward guidance

The filing discusses Tango Therapeutics's outlook, capital deployment, and key risks without relying solely on numeric EPS guidance.

Tailwinds

  • Tango Therapeutics cites execution on strategic priorities in the filing.
  • Balance sheet and liquidity support continued operations.
  • Pipeline milestones and cash runway remain key value drivers.

Headwinds

  • Macro, competitive, and cost pressures may affect margins.
  • Segment mix and one-time items can affect comparability.
  • Clinical-stage or pre-commercial spend continues ahead of revenue scale.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q3 2025

Historical avgQ3 2025

+0.6%

Avg return

Earnings day

+6.7%

Avg return

5 days after

+25.8%

Avg return

30 days after

58%

11 / 19 earnings

Positive

+36.4%

Q4 2025

Best reaction

-45.4%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+8.6%-12.1%+31.7%
Q4 2025+36.4%+33.6%+75.1%
Q3 2025+0.2%-1.7%+23.6%
Q1 2025+17.1%+31.6%+315.8%
Q4 2024-6.5%-21.0%-36.9%
Q3 2024-45.4%-34.7%-34.7%
Q2 2024-1.8%-5.7%+20.9%
Q1 2024-0.8%-6.9%-12.1%
Q4 2023-9.7%-14.4%-17.4%
Q3 2023+3.8%-12.1%+6.6%
Q2 2023+1.2%+120.9%+113.5%
Q1 2023+6.4%+4.4%-0.3%
Q4 2022-9.4%-5.3%-21.6%
Q3 2022-5.3%+6.7%-1.3%
Q2 2022+22.4%+32.8%-8.1%
Q1 2022-7.6%+1.2%-3.8%
Q4 2021+0.3%+6.8%+1.3%
Q3 2021+0.4%+5.2%-10.7%
Q2 2021+1.1%-2.2%+49.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro